Company

Waypoint Bio, Inc.

Waypoint Bio develops cell therapies for solid tumors and autoimmune diseases.

About

Founded in 2021 and based in New York, Waypoint Bio uses spatial biology and in vivo testing to develop cell therapies for cancer and autoimmune diseases. Its platform screens and measures cell therapy designs using computer vision and protein design. In May 2026, it raised USD 20 million in Series A funding led by Amplify Partners, with participation from General Catalyst Partners, Lux Capital, Mitsui Global Investment, Time BioVentures and Hummingbird Ventures.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in